Pegylated liposomal doxorubicin in ovarian cancer.

Abstract

Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.

• Authors: Andrew E Green, Peter G Rose
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 1 Issue 3 Pg. 229-39 ( 2006) ISSN: 1176-9114 [Print] New Zealand
• PMID: 17717964 (Publication Type: Journal Article, Review)

Chemical References

• Antibiotics, Antineoplastic
• Drug Carriers
• Liposomes
• Polyethylene Glycols
• Doxorubicin

Topics

• Antibiotics, Antineoplastic (administration & dosage, chemistry)
• Doxorubicin (administration & dosage, chemistry)
• Drug Carriers (chemistry)
• Female
• Humans
• Liposomes (chemistry)
• Nanomedicine (methods)
• Ovarian Neoplasms (drug therapy)
• Polyethylene Glycols (chemistry)